Efficacy and safety of anti-COVID-19 vaccination in patients with autoimmune blistering diseases: A French national study - 13/12/23
Doi : 10.1016/j.jaad.2023.08.101
Sokounthie Ou, MD a, Emmanuelle Tancrède-Bohin, MD b, Marina Alexandre, MD c, Saskia Ingen-Housz-Oro, MD d, Marion Castel, MD e, Sébastien Debarbieux, MD f, Sophie Duvert-Lehembre, MD g, h, Maria Polina Konstantinou, MD i, Claire Abasq, MD j, Clémence Berthin, MD k, Caroline Couzan, MD l, Clémence Lepelletier, MD b, Lamia Jelti, MD d, Julie Bouteiller, MD e, Andreea Calugareanu, MD m, Marie Véron, MD g, Frédéric Caux, MD, PhD c, Pascal Joly, MD, PhD e, Bérenger Thomas, MSc n, Manuelle Viguier, MD, PhD a, ⁎ 
on behalf of the
on behalf of the
French Study Group on Autoimmune Bullous Skin Diseases
a Department of Dermatology, Reims University Hospital, Centre de Référence des Maladies Bulleuses Auto-immunes, MALIBUL and EA7509, IRMAIC, Université Reims-Champagne Ardenne, Reims, France
b Department of Dermatology, Saint-Louis Hospital, Assistance Publique – Hôpitaux de Paris, Paris, France
c Department of Dermatology, Groupe Hospitalier Paris Seine-Saint-Denis, Centre de Référence des Maladies Bulleuses Auto-immunes, MALIBUL and INSERM UMR1125, Bobigny, France
d Department of Dermatology, Henri-Mondor University Hospital, Assistance Publique – Hôpitaux de Paris, University Paris Est Créteil, EpidermE, Créteil, France
e Department of Dermatology, Rouen University Hospital, Centre de Référence des Maladies Bulleuses Auto-immunes, MALIBUL and INSERM U1234, Normandie University, Rouen, France
f Department of Dermatology, Hospices Civils de Lyon, Lyon Sud Hospital, Lyon, France
g Department of Dermatology, Lille University Hospital, Lille, France
h Department of Dermatology, Dunkerque Hospital, Dunkerque, France
i Department of Dermatology, Larrey Hospital, Toulouse, France
j Department of Dermatology, Augustin-Morvan Hospital, Brest, France
k Department of Dermatology, Angers Hospital, Angers, France
l Department of Dermatology, Saint-Étienne Hospital, Saint-Étienne, France
m Department of Dermatology, Édouard Herriot Hospital, Lyon, France
n Department of Epidemiology, Faculty of Medicine, Sorbonne University, Paris, France
∗Correspondence to: Manuelle Viguier, MD, PhD, Department of Dermatology, Reims University Hospital, Centre de Référence des Maladies Bulleuses Auto-immunes, MALIBUL and EA7509, IRMAIC, Université Reims-Champagne Ardenne, Avenue du Général Koenig, 51100 Reims, FranceDepartment of Dermatology, Reims University Hospital, Centre de Référence des Maladies Bulleuses Auto-immunes, MALIBUL and EA7509, IRMAIC, Université Reims-Champagne ArdenneAvenue du Général KoenigReims51100France
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Key words : autoimmune bullous disease, COVID-19, efficacy, flare, immunosuppression, infection, safety, SARS-CoV-2, vaccination
| Funding sources: None. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Reviewed and approved by the Règlement Général de Protection des Données (MR00426042023). |
© 2023
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 90 - N° 1
P. 204-208 - janvier 2024 Retour au numéro
Article précédent
- Clinical epidemiology of tumid lupus erythematosus: A retrospective review of 179 patients
- Stephanie Sanchez-Melendez, Rhea Malik, Ruhi Kanwar, Kevin Yang, Vinod E. Nambudiri
- Impact of time to surgical treatment in Merkel cell carcinoma: Surveillance, Epidemiology, and End Results–based population study
- Stephanie K. Lin, Annika M. Deitermann, Dylan Haynes, Kaley Ricciardelli, Jeremy R. Etzkorn, Christopher J. Miller, H. William Higgins, Cerrene N. Giordano, Stacy L. McMurray, Joanna L. Walker, Junqian Zhang, Harrison P. Nguyen, Joseph F. Sobanko
Bienvenue sur EM-consulte, la référence des professionnels de santé.